Kiora's stock rallies as eye drop treatment moves into mid-stage clinical trial
2/7/23 8:01 AM ET (MarketWatch)Print
Shares of Kiora Pharmaceuticals Inc. (KPRX) soared about 57% in premarket trading on Tuesday after the company said it will begin a Phase 2 clinical trial for its experimental eye drops as a treatment for ocular rheumatoid arthritis. The study plans to enroll 120 patients in the first half of the year. Kiora's stock is down 87.9% over the past year, while the S&P 500 has declined 7.1%.
(END) Dow Jones Newswires
February 07, 2023 08:01 ET (13:01 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.